Reports Q4 revenue $93.4M, consensus $90.01M. “The impressive growth we are seeing with ORLADEYO has put us in a position to accelerate our path to profitability while continuing to invest in our diverse pipeline of first-in-class or best-in-class molecules that we believe will deliver our next marketed product,” said Jon Stonehouse, president and chief executive officer of BioCryst.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BCRX:
- BCRX Earnings this Week: How Will it Perform?
- BioCryst presents real-world data on ORLADEYO
- BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment
- BioCryst to Present at Upcoming Investor Conferences
- BioCryst Pharmaceuticals announces launch of ORLADEYO in Italy
